FDA Committee Backs AstraZeneca's Vandetanib For Narrower Population Of Thyroid Cancer Patients

Majority of the Oncologic Drugs Advisory Committee members support use in patients with progressive or symptomatic medullary thyroid cancer, a more limited indication than that proposed by the sponsor.